Agents and Actions

, Volume 17, Issue 2, pp 192–196 | Cite as

Cyclic nucleotide phosphodiesterase inhibition by a benzoic acid derivative

  • John J. F. Killackey
  • Barbara A. Killackey
  • Richard B. Philp
Immunosuppression and Inflammation


Acetylsalicylic acid (ASA) and three structurally related benzoic acid derivatives, 2-acetylbenzoic acid (ABA), 3-methylphthalide (3-MP), and 3-hydroperoxy-3-methylphthalide (3-HMP), were tested for inhibitory effects on three human blood platelet cyclic nucleotide phosphodiesterase (PDE) activities. 3-MP caused a dose-dependent inhibition of the high and low affinity cyclic AMP PDE activities and the cyclic GMP PDE activity. 3-HMP had some inhibitory effects but only on the low affinity cyclic AMP PDE activity. ASA and ABA had no effects. This study shows that progressive structural changes in the ASA molecule can shift the pharmacological profile from a cyclooxygenase inhibitor (ASA) to an inactive compound (ABA) to a PDE inhibitor (3-MP) and back again to a cyclooxygenase inhibitor (3-HMP). It is proposed that the potent anti-inflammatory effects of 3-MP, which differ from those of ASA, are mediated through the inhibition of the cyclic nucleotide PDE system.


Acetylsalicylic Acid Cyclic Nucleotide Phosphodiesterase Inhibition Cyclooxygenase Inhibitor Inactive Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    I. Cerskus andR. B. Philp,Relationship of inhibition of prostaglandin synthesis in platelets to anti-aggregatory and anti-inflammatory activity of some benzoic acid derivatives, Agents and Actions11, 281–286 (1981).PubMedGoogle Scholar
  2. [2]
    E.A. Ham, V.J. Cirillo, M.E. Zanetti, T.Y. Shen andF.A. Kuehl Jr., Studies on the mode of action of nonsteroidal anti-inflammatory agents. InProstaglandins in Cellular Biology, pp. 345–352 (EdsP.W. Ramwell andB.B. Pharriss). Plenum, New York 1972.Google Scholar
  3. [3]
    J.J.F. Killackey, B.A. Killackey andR.B. Philp,The effects of some benzoic acid derivatives on polymorphonuclear leukocyte accumulation in vivo, Int. J. Immunopharmacol. (in press) (1985).Google Scholar
  4. [4]
    J.J.F. Killackey, B.A. Killackey andR.B. Philp,Structure-activity studies of aspirin and related compounds on platelet aggregation, arachidonic acid metabolism in platelets and artery and arterial prostacyclin activity, Prostaglandins Leukotrienes Med.9, 9–23 (1982).CrossRefGoogle Scholar
  5. [5]
    R.R. Gorman, S. Bunting andO.V. Miller,Modulation of human platelet adenylate cyclase by prostacyclin (PGX), Prostaglandins13, 377–388 (1977).CrossRefPubMedGoogle Scholar
  6. [6]
    W.J. Thompson, W.L. Teraski, P.M. Epstein andS.J. Strada,Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme, Adv. Cyclic Nucleotide Res.10, 69–92 (1979).PubMedGoogle Scholar
  7. [7]
    F.A. McElroy andR.B. Philp,Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechanism of inhibition of platelet function, Life Sciences17, 1479–1494 (1975).CrossRefPubMedGoogle Scholar
  8. [8]
    B.A. McIntyre andR.B. Philp,Effects of three nonsteroidal anti-inflammatory agents on platelet function and prostaglandin synthesis in vitro, Thromb. Res.12, 67–77 (1977).CrossRefGoogle Scholar
  9. [9]
    H. Hidaka andT. Asano,Human platelet 3′, 5′-cyclic nucleotide phosphodiesterase: isolation of the low K m and high K m phosphodiesterase, Biochim. Biophys. Acta429, 485–497 (1976).PubMedGoogle Scholar
  10. [10]
    A.L. Pichard andW.Y. Cheung,Cyclic 3′, 5′-nucleotide phosphodiesterase: interconvertible multiple forms and their effects on enzyme activity and kinetics, J. Biol. Chem.251, 5726–5737 (1976).PubMedGoogle Scholar
  11. [11]
    B.J. Weiss andW.W. Hait,Selective cyclic nucleotide phosphodiesterase inhibitors as potential therapeutic agents, Ann. Rev. Pharmacol. Toxicol.17, 441–447 (1977).CrossRefGoogle Scholar
  12. [12]
    J.R. Vane,Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs, Nature (New Biology)231, 232–235 (1971).Google Scholar
  13. [13]
    A. Beretz, A. Stierle, R. Anton andJ.P. Cazenave,Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin, Biochem. Pharmacol.31, 3597–3600 (1982).CrossRefPubMedGoogle Scholar
  14. [14]
    D. Ruppert andK. Weithman,HL 725, An extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro, Life Sciences31, 2037–2045 (1982).CrossRefPubMedGoogle Scholar
  15. [15]
    H. Mikashima, T. Nakao, K. Goto, H. Ochi, H. Yasuda andT. Tsumagari,Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent — II. Inhibition of platelet phosphodiesterase, Thromb. Res.35, 589–594 (1984).CrossRefPubMedGoogle Scholar
  16. [16]
    T. Glaser andJ. Traber,TVX 2706 — A new phosphodiesterase inhibitor with anti-inflammatory action. Biochemical characterization., Agents and Actions,15, 341–348 (1984).PubMedGoogle Scholar
  17. [17]
    D.E. Knight andM.C. Scrutton,Cyclic nucleotides control a system which regulates Ca 2+ sensitivity of platelet secretion, Nature309, 66–68 (1984).CrossRefPubMedGoogle Scholar
  18. [18]
    M.M.L. Davidson andR.J. Haslam Role of cyclic nucleotides in the inhibition of platelet function by nitroprusside and by ascorbate, Thromb. Haemostas.46, 149 (1981).Google Scholar
  19. [19]
    B.T. Mellion, L.J. Ignarro, C.B. Meyers, E.H. Ohlstein, B.A. Ballot, A.K. Hyman andP.J. Kadowitz,Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation, Mol. Pharmacol.23, 653–664 (1983).PubMedGoogle Scholar
  20. [20]
    M. Hagiwara, T. Endo, T. Kanayama andH. Hidaka,Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation, J. Pharmacol. Exp. Therap.228, 467–471 (1984).Google Scholar
  21. [21]
    R.J. Haslam andM.M.L. Davidson,GTP not cyclic GMP enhances secretion from permeabilized platelets, Nature313, 821–822 (1985).CrossRefPubMedGoogle Scholar
  22. [22]
    R. Vinegar, J.F. Truax, J.L. Selph, R.M. Welch andH.L. White,Potentiation of the anti-inflammatory and analgesic activity of aspirin by caffeine in the rat, Proc. Soc. Exp. Biol. Med.151, 556–560 (1976).PubMedGoogle Scholar
  23. [23]
    P.S. Schonhoffer, J. Sohn, H.D. Peters andV. Dimmendahl,Effect of sodium salicylate and acetylsalicylic acid on the lipolytic system of fat cells, Biochem. Pharmacol.22, 629–637 (1973).CrossRefPubMedGoogle Scholar
  24. [24]
    D.S. Newcombe, W.M. Thenassi andC.P. Ciosek Jr.,Cartilage cyclic nucleotide phosphodiesterase: inhibition by anti-inflammatory agents, Life Sciences14, 505–519 (1974).CrossRefPubMedGoogle Scholar
  25. [25]
    V. Stefanovich,Inhibition of 3′, 5′-cyclic AMP phosphodiesterase with anti-inflammatory agents, Res. Commun. Chem. Pathol. Pharmacol.7, 573–582 (1974).PubMedGoogle Scholar
  26. [26]
    J.G. Rafanell, J.M. Planas andP. Puig-Parellada,Comparison of the inhibitory effects, of acetylsalicylic acid and triflusal on enzymes related to thrombosis, Arch. Int. Pharmacodyn. Therap.237, 343–355 (1979).Google Scholar
  27. [27]
    J.J.F. Killackey, B.A. Killackey, I. Cerskus andR.B. Philp,Anti-inflammatory properties of a hydroperoxide compound, structurally related to acetylsalicylic acid, Inflammation8, 157–169 (1984).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1985

Authors and Affiliations

  • John J. F. Killackey
    • 1
  • Barbara A. Killackey
    • 1
  • Richard B. Philp
    • 1
  1. 1.Department of Pharmacology and ToxicologyUniversity of Western OntarioLondon

Personalised recommendations